Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.

Activating mutations in signaling molecules, such as JAK2-V617F, have been associated with myeloproliferative neoplasms (MPNs). Mice lacking the inhibitory adaptor protein Lnk display deregulation of thrombopoietin/thrombopoietin receptor signaling pathways and exhibit similar myeloproliferative characteristics to those found in MPN patients, suggesting a role for Lnk in the molecular pathogenesis of these diseases. Here, we showed that LNK levels are up-regulated and correlate with an increase in the JAK2-V617F mutant allele burden in MPN patients. Using megakaryocytic cells, we demonstrated that Lnk expression is regulated by the TPO-signaling pathway, thus indicating an important negative control loop in these cells. Analysis of platelets derived from MPN patients and megakaryocytic cell lines showed that Lnk can interact with JAK2-WT and V617F through its SH2 domain, but also through an unrevealed JAK2-binding site within its N-terminal region. In addition, the presence of the V617F mutation causes a tighter association with Lnk. Finally, we found that the expression level of the Lnk protein can modulate JAK2-V617F-dependent cell proliferation and that its different domains contribute to the inhibition of multilineage and megakaryocytic progenitor cell growth in vitro. Together, our results indicate that changes in Lnk expression and JAK2-V617F-binding regulate JAK2-mediated signals in MPNs.

[1]  Erin F. Simonds,et al.  Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. , 2010, Blood.

[2]  Mondira Kundu,et al.  Lnk constrains myeloproliferative diseases in mice. , 2010, The Journal of clinical investigation.

[3]  J. Soulier,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[4]  S. Gery,et al.  Lnk inhibits myeloproliferative disorder‐associated JAK2 mutant, JAK2V617F , 2009, Journal of leukocyte biology.

[5]  W. Hofmann,et al.  Expression of the adaptor protein Lnk in leukemia cells. , 2009, Experimental hematology.

[6]  N. Varin‐Blank,et al.  Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells. , 2008, Blood.

[7]  R. Geffers,et al.  SOCS2: inhibitor of JAK2V617F-mediated signal transduction , 2008, Leukemia.

[8]  Chao Wu,et al.  Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. , 2008, The Journal of clinical investigation.

[9]  Hiu Kiu,et al.  SOCS regulation of the JAK/STAT signalling pathway. , 2008, Seminars in cell & developmental biology.

[10]  D. Kent,et al.  Steel factor coordinately regulates the molecular signature and biologic function of hematopoietic stem cells. , 2008, Blood.

[11]  H. Nakauchi,et al.  Growth and maturation of megakaryocytes is regulated by Lnk/Sh2b3 adaptor protein through crosstalk between cytokine- and integrin-mediated signals. , 2008, Experimental hematology.

[12]  W. Vainchenker,et al.  primitive myelofibrosis Evidence for MPL W515L/K mutations in hematopoietic stem cells in , 2013 .

[13]  S. Gery,et al.  Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders. , 2007, Blood.

[14]  Mary Frances McMullin,et al.  The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. , 2007, Blood.

[15]  T. Maures,et al.  SH2B1 (SH2-B) and JAK2: a multifunctional adaptor protein and kinase made for each other , 2007, Trends in Endocrinology & Metabolism.

[16]  H. Nakauchi,et al.  Lnk negatively regulates self-renewal of hematopoietic stem cells by modifying thrombopoietin-mediated signal transduction , 2007, Proceedings of the National Academy of Sciences.

[17]  W. Vainchenker,et al.  Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. , 2007, Blood.

[18]  D. Gilliland,et al.  MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. , 2006, Blood.

[19]  G. Massonnet,et al.  High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. , 2006, Blood.

[20]  O. Silvennoinen,et al.  Binding of SH2-B Family Members within a Potential Negative Regulatory Region Maintains JAK2 in an Active State , 2006, Molecular and Cellular Biology.

[21]  K. Anderson,et al.  Cytokines regulate postnatal hematopoietic stem cell expansion: opposing roles of thrombopoietin and LNK. , 2006, Genes & development.

[22]  Sandra A. Moore,et al.  MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.

[23]  K. Kaushansky,et al.  The molecular mechanisms that control thrombopoiesis. , 2005, The Journal of clinical investigation.

[24]  Qingshan Li,et al.  Identification of an Acquired JAK2 Mutation in Polycythemia Vera* , 2005, Journal of Biological Chemistry.

[25]  H. Lodish,et al.  Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. , 2005, Blood.

[26]  H. Nakauchi,et al.  Quantification of self-renewal capacity in single hematopoietic stem cells from normal and Lnk-deficient mice. , 2005, Developmental cell.

[27]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[28]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[29]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[30]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[31]  M. Cazzola,et al.  Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders. , 2005, Haematologica.

[32]  Harvey F. Lodish,et al.  Lnk Inhibits Tpo–mpl Signaling and Tpo-mediated Megakaryocytopoiesis , 2004, The Journal of experimental medicine.

[33]  H. Cavé,et al.  Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.

[34]  T. Pawson,et al.  Cytokine Signaling and Hematopoietic Homeostasis Are Disrupted in Lnk-deficient Mice , 2002, The Journal of experimental medicine.

[35]  H. Miyazaki,et al.  Elevation of serum thrombopoietin precedes thrombocytosis in acute infections , 2002, British journal of haematology.

[36]  Satoshi Takaki,et al.  Enhanced Hematopoiesis by Hematopoietic Progenitor Cells Lacking Intracellular Adaptor Protein, Lnk , 2002, The Journal of experimental medicine.

[37]  C. Rudd.  Lnk Adaptor: Novel Negative Regulator of B Cell Lymphopoiesis , 2001, Science's STKE.

[38]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[39]  J. Herrington,et al.  Differential Binding to and Regulation of JAK2 by the SH2 Domain and N-Terminal Region of SH2-Bβ , 2000, Molecular and Cellular Biology.

[40]  S. Schwartz.  Myeloproliferative Disorders , 1975, Annals of surgery.